Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method

Bibliography

• Luthra PM, Barodia SK, Raghubir R. Antagonism of haloperidol-induced swim impairment in l-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. J Neurosci Methods 2009;178:284-90
   PubMed Web of Science ®Google Scholar
• Verma R, Nehru B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem Int 2009;55:369-75
   PubMed Web of Science ®Google Scholar
• Muthane UB, Ragothaman M, Gururaj G. Epidemiology of Parkinson's disease and movement disorders in India: problems and possibilities. J Assoc Physicians India 2007;55:719-24
   PubMedGoogle Scholar
• Md S, Haque S, Sahni JK, et al. New non-oral drug delivery systems for Parkinson's disease treatment. Expert Opin Drug Deliv 2011;8(3):359-74
   PubMed Web of Science ®Google Scholar
• Gárdián G, Vécsei L. Medical treatment of Parkinson's disease: today and the future. Int J Clin Pharmacol Ther 2010;48:633-42
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
   PubMed Web of Science ®Google Scholar
• Fazil M, Shadab M, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47(1):6-15
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiang M, Kang T, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013;34:3870-81
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 2011;151:131-8
   PubMed Web of Science ®Google Scholar
• Vila A, Sanchez A, Tobio M, et al. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24
   PubMed Web of Science ®Google Scholar
• Haque S, Shadab M, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting, pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012;89(1):72-9
   PubMed Web of Science ®Google Scholar
• Ieva E, Trapani A, Cioffi N, et al. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications. Anal Bioanal Chem 2009;393:207-15
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhang B, Whent M, et al. Preparation and characterization of zein/chitosan complex for encapsulation of tocopherol, and its in vitro controlled release study. Colloids Surf B Biointerfaces 2011;85:145-52
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SS, Boo DH, et al. Protective effect of bromocriptine against BH4-induced Cath. A cell death involving up-regulation of antioxidant enzymes. Neurosci Lett 2009;451(3):185-9
   PubMed Web of Science ®Google Scholar
• Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 2013;48(3):393-05
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45(2):109-36
   PubMed Web of Science ®Google Scholar
• Degim IT, Acartürk F, Erdogan D, Lortlar ND. Transdermal administration of bromocriptine. Biol Pharm Bull 2003;26(4):501-5
   PubMed Web of Science ®Google Scholar
• Choi YJ, Seo MK, Kim IC, Lee YH. High-performance liquid chromatographic assay of bromocriptine in plasma and eye tissue of the rabbit. J Chromatogr B Biomed Sci Appl 1997;694:415-20
   PubMed Web of Science ®Google Scholar
• Valente D, Ezan E, Créminon C, et al. Enzyme immunoassays for bromocriptine and its metabolites. J Immunoassay 1996;17(4):297-20
   PubMedGoogle Scholar
• Salvador A, Dubreuil D, Denouel J, Millerioux L. Sensitive method for the quantitative determination of bromocriptine in human plasma by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;820:237-42
   PubMed Web of Science ®Google Scholar
• Faiyazuddin M, Ahmad N, Khar RK, et al. Stabilized terbutaline submicron drug aerosol for deep lungs deposition: drug assay, pulmonokinetics and biodistribution by UHPLC/ESI-q-TOF-MS method. Int J Pharm 2012;434:59-69
   PubMed Web of Science ®Google Scholar
• Md S, Kumar M, Baboota S, et al. Preparation, characterization and evaluation of bromocriptine loaded chitosan nanoparticles for intranasal delivery. Sci Adv Mater 2012;4(9):949-60
   Web of Science ®Google Scholar
• Dudhani AR, Kosaraju SL. Bioadhesive chitosan nanoparticles: preparation and characterization. Carbohydr Polym 2010;81:243-51
   Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2010;6(1):144-52
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Bobade N, et al. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 2010;18(3):223-34
   PubMed Web of Science ®Google Scholar
• ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). ICH harmonised tripartite guideline 2005 [Last assessed 6 January 2014]
   Google Scholar
• ICH harmonised tripartite guideline. Stability testing of New Drug Substances and Products Q1A(R2). ICH harmonised tripartite guideline 2003 [Last assessed 6 January 2014]
   Google Scholar
• Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358(1-2):285-91
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70(3):735-40
   PubMed Web of Science ®Google Scholar
• Fenli S, Wang F, Zhu R, Li H. Determination of 5-hydroxytryptamine norepinephrine, dopamine and their metabolites in rat brain tissue by LC–ESI–MS–MS. Chromatographia 2009;69:207-13
   Web of Science ®Google Scholar
• Trapani A, De Giglio E, Cafagna D, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm 2011;419:296-07
   PubMed Web of Science ®Google Scholar
• Nageswari A, Reddy KV, Mukkanti K. Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J Pharm Biomed Anal 2012;66:109-15
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. J Drug Target 2010;18(5):381-8
   PubMed Web of Science ®Google Scholar
• Zhu Z, Bartol M, Shen K, Johnson SW. Excitatory effects of dopamine on subthalamic nucleus neurons: in vitro study of rats pretreated with 6-hydroxydopamine and levodopa. Brain Res 2002;945:31-40
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6
   PubMed Web of Science ®Google Scholar
• Morris GA, Castile J, Smith A, et al. The effect of prolonged storage at different temperatures on the particle size distribution of tripolyphosphate (TPP)–chitosan nanoparticles. Carbohydr Polym 2011;84:1430-4
   Web of Science ®Google Scholar
• Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration. Int J Pharm 2011;416:331-8
   PubMed Web of Science ®Google Scholar